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To the Editor: Cystic fibrosis (CF) is present in all South A f r i c a n
population groups.  In a significant proportion of patients a
diagnosis of CF can be confirmed by DNAanalysis and the
detection of two CF transmembrane conductance regulator (CFTR)
mutations, using the panels of mutations developed in this study.
The index of suspicion will also be raised in patients with a single
CFTR mutation.  DNAtesting is important, especially in re g i o n s
without access to reliable sweat tests, and should be considered an
aid to diagnosis.  In addition to receiving appropriate tre a t m e n t ,
patients and their families can receive more accurate genetic
counselling, CF carrier testing and prenatal diagnosis.
CF is one of the commonest autosomal recessive disord e r s
among white South Africans, with a prevalence of 1 in 2 000;
p revalence in the coloured population is 1 in 12 000.1 CF was
initially thought to be extremely rare in African blacks but a re c e n t
study showed a carrier frequency of 1 in 34 and a calculated
incidence of 1 in 4 624 births.2
CF is characterised by pancreatic insuff i c i e n c y, chro n i c
pulmonary disease, elevated sweat chloride levels and a number of
other features.  It can be difficult to diagnose because of the gre a t
variability of clinical presentation and severity.  The UK CF
Foundation Consensus Panel suggests confirmation of diagnosis
only after two positive sweat test results on separate occasions in a
patient with suggestive clinical feature s .3 H o w e v e r, as a diagnostic
test the sweat test is not ideal.  It re q u i res extreme technical rigour
by experienced staff using standardised methods.  In large parts of
South Africa such services are not readily available.
An alternative method of diagnosis became possible with the
cloning of the CFTR gene.4 CF is caused by mutations in the CFTR
gene — patients have two mutations and carriers have one.  Over
1 000 mutations have been identified.5 Patients may have two
identical mutations (homozygotes) or two diff e rent mutations
(compound heterozygotes), but the identification of two CF
mutations in a patient confirms the diagnosis of CF.
Given the number of CF-causing mutations and the
impracticality of screening the large CFTR gene, testing for
mutations that are common in a particular population makes
genetic testing useful as a diagnostic tool.  The aim of this study
was to improve the sensitivity and efficiency of diagnostic genetic
testing for CF in South Africa through the development of
customised panels of mutations for diff e rent South A f r i c a n
population groups.  Atotal of 201 white, 43 coloured and 14 black
CF patients with confirmed diagnoses were included in this pro j e c t
for CFTR mutation analysis.  
White and coloured patients were tested for 24 mutations
including ▲F508, 394delTT, Q493X, 3272-26A → G, 3120+1G→ A ,
R 117H, 3659delC, G542X, G551D, R553X, 621+1G → T, W1282X,
N1303K, 1717-1G → A, R1162X, R334W, 3849+10kbC → T, A 4 5 5 E ,
2 1 8 3 A A → G, 1078delT, ▲I507, R347P, S1251N, and E60X.  Five
c o l o u red patients in whom small amounts of DNA w e re available
f rom buccal scrapes were only tested for the ▲F508 mutation.
Black patients were initially tested for the 3120 +1G →A m u t a t i o n .
Those black patients whose mutations were still unidentified were
tested for the ▲F508 mutation.  Mutation detection assays have
been described pre v i o u s l y.6
Significant diff e rences in the CFTR mutation distribution were
found between groups, supporting the notion that population-
specific panels of mutations are re q u i red when using genetic tests
to diagnose CF (Table I).  Sixteen mutations were detected in the
South African white population, accounting for 91% of all CFTR
mutations in this population.   In the coloured population, the
▲F508 and 3120+1G→Amutations occur at appre c i a b l e
f requencies and account for 74.4 % (64/86) of mutations. In the
black population, 60.7% of mutations (17/28) were identified,
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including five diff e rent mutations.  The most common mutation is
3 1 2 0 + 1 G→A, which occurs at a frequency of 46% (13/28).  Four
patients were homozygous for this mutation.  Four other
mutations (each on a single chromosome) have been identified.6
Fig. 1 shows the breakdown of the expected proportion of CFTR
genotypes after testing a suspected CF patient using customised
panels of mutations developed in this project.  In the white
population, 83% of CF patients will have two identifiable
mutations (M/M) confirming a diagnosis of CF. Similarly, after
D N A analysis alone, 55% of coloured but only 21% of black CF
patients can be definitively diagnosed as having CF. The re m a i n i n g
CF patients will have either one identified mutation (M/U) or no
identified mutations (U/U).  In black CF patients, 71% will show at
least one 3120+1G → Amutation after DNAanalysis, thus
assisting the clinician in making a diagnosis.  Confirmation of the
diagnosis in such patients will only be possible with clear clinical
f e a t u res and/or two positive sweat tests.
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Table I. Frequency of common CFTR mutations in cystic fibrosis
patients from different South African population groups
White Coloured Black
Mutation (N = 201)* (N = 43)* (N = 14)*
▲F508 0.76 0.500 -
3272-26A → G 0.040 0.012 -
3120+1G → A 0.005 0.174 0.464
394delTT 0.037 - -
G542X 0.017 0.023 -
R553X 0.01 - -
W1282X 0.01 - -
N1303K 0.01 - -
G551D 0.008 0.023 -
R117H 0.0025 - -
Q493X 0.0025 - -
S549N 0.0025 - -
621+1G → T 0.0025 - -
1717-1G → A 0.0025 - -
2789+5G → A 0.0025 - -
3659delC 0.0025 - -
R1162X - 0.012 -
G1249E† - - 0.036
3196del54† - - 0.036
-94G → T† - - 0.036
2183delAA† - - 0.036
Unknown 0.086 0.256 0.393
Total mutation detection 0.910 0.744 0.607
* N = number of patients studied.
† These patients were reported previously. 5 6













Fig. 1. Pie charts illustrating the proportion of South African CF
patients who can be diagnosed by DNA analysis when testing for the
common mutations included in the diagnostic panels. (a) white
CFTR mutation panel: 15 mutations (91% mutation detection); (b)
coloured CFTR mutation panel: 16 mutations (74% mutation
detection); (c) black CFTR mutation panel: 3120+1G → A (46%
mutation detection). M= mutation identified;  U= mutation
unknown; M/M = two identified CFTR mutations; M/U = one
identified CFTR mutation; U/U = no identified CFTR mutations.
